Pricing Log in Create free account
Saturday 17 October 2026 Export BDRX’s income statement to Excel — free account

Biodexa Pharmaceuticals PLC Unsponsored ADR

BDRX Healthcare Biotechnology

Biodexa Pharmaceuticals PLC Unsponsored ADR’s revenue for fiscal 2023 (year ended December 2023) was $473,900.00, down 45.2% from fiscal 2022.

0.46 0.03 +6.98%
Market cap
$440.0K
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
−21.37
Beneish M
100.49
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 79.36%

Capital & Financial Ratios $m

Market Cap 0.44
Revenue 1.46
Net Income (23.30)
Free Cash Flow (33.64)
Net Debt (4.33)
Current Ratio 2.41 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E —
P/S ratio 0.00
P/B ratio 0.00
Past 5Y EPS Growth —
This Y EPS Growth 100.00% (at or above 15%: strong)
Next Y EPS Growth 0.00%
Next Y revenue growth (93.97%) (below 0%: weak)
Next 5Y EPS Growth 89.98% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is −2.8×, against a ten-year median of −4.0×; over the ten years it ranged from −14.5× in 2020 to −0.8× in 2024.
EV/FCF against its own 10 years 28.49%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2020 Powerpack
2019 Powerpack
2018 Powerpack
2017 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 7 2 11 4
Receivables 1 9 5 5
Inventory — — — —
Other — — — —
9 11 16 9
2023 2024 2025 Q'26
Payables 2 4 3 2
ST’ Debt 0 1 0 —
Other 5 1 5 2
7 6 8 4

Compound Annual Growth %

10y 5y 3y
Sales — (28.78%) 2.47%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value (14.46%) 11.76% 56.67%

Revenue $m

Mar Jun Sep Dec Year
’26 — — — — —
’23 — — — — 0
’22 — — — — 1
’21 — — — — 1
’20 — — — — 0
’19 — — — — 1
’18 — — — — 3
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 — — — — —
’25 — — — — (7)
’24 — — — — (16)
’23 — — — — (8)
’22 — — — — (9)
’21 — — — — (8)
’20 — — — — (12)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 — (7) — — —
’25 — (5) — (7) (8)
’24 — (7) — (16) (17)
’23 — (5) — (9) (9)
’22 — (4) — (9) (9)
’21 — (5) — (9) (9)
’20 — (9) — (12) (12)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 — — — — —
’25 — — — — (65.95)
’24 — — — — (639.00)
’23 — — — — (12.44k)
’22 — — — — (959.00k)
’21 — — — — (0.47)
’20 — — — — (3.33)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 240,000,000.00 79,000,000.00 12,300,000.00 5,400,000.00 1,724,000.00 2,030,000.00 268,000.00 2,562.50 175.00 11.10

Analyst estimates 2026–2028

Powerpack
High 572,000,000.00 365,000,000.00 265,000,000.00 109,000,000.00 14,140,000.00 7,660,000.00 2,660,000.00 396,000.00 3,700.00 460.00
People
People Employees 79 85 73 65 18 20 27 21 13 11
Revenue/emp, $m 0.12 0.12 0.04 0.01 0.02 0.04 0.03 0.02 0.00 0.00
Income, $m
Income, $m Revenue 9 10 3 1 0 1 1 0 — —
Gross margin, % 90.37 87.81 100.00 100.00 100.00 100.00 100.00 100.00 — —
EBT (40) (22) (17) (14) (30) (8) (10) (9) (8) (9)
EBT margin, % (423.55) (228.07) (639.84) (1,620.68) (6,842.76) (1,056.42) (1,214.30) (1,964.68) 0.00 0.00
Net income (27) (21) (20) (13) (28) (8) (9) (9) (7) (8)
Depreciation 6 3 2 2 2 1 0 0 0 0
Per share, $
Per share, $ Revenue 0.52 0.38 0.85 0.23 0.05 0.05 0.00 789.83 0.00 0.00
Earnings (1.51) (0.81) (6,600,000.00) (7,020,000.00) (3.33) (0.47) (959,000.00) (12,437.50) (639.00) (65.95)
Cash flow (0.98) (0.65) (5.87) (2.26) (1.39) (0.51) 0.00 (14,151.50) (1,582.66) (67.21)
Capex (0.10) (0.07) (0.10) (0.11) (0.01) (0.02) 0.00 (537.00) (99.91) (8.09)
Free cash flow (1.09) (0.73) (5.97) (2.37) (1.40) (0.54) 0.00 (14,688.50) (1,682.57) (75.30)
Book value 3.44 1.74 7.39 6.81 1.01 0.89 0.00 9,698.33 1,074.21 137.10
Shares, m 18 26 3 4 9 16 0 0 0 0
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 — —
P/S 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 — —
P/B 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 — —
EV/Sales 0.00 0.00 0.00 0.00 (14.51) (12.26) (1.67) (4.70) — —
EV/FCF 0.34 0.14 0.02 0.14 0.26 0.37 0.10 0.26 — —
Cash, $m
Cash, $m Operating cash flow (18) (17) (18) (8) (12) (8) (9) (8) (16) (7)
Capex (2) (2) 0 0 0 0 0 0 (1) (1)
Free cash flow (20) (19) (18) (9) (12) (9) (9) (9) (17) (8)
Balance, $m
Balance, $m Working capital 18 13 4 10 8 14 3 2 5 8
Total debt 3 8 2 8 0 1 1 1 1 0
Net debt (21) (9) (1) (6) (9) (13) (3) (7) (1) (11)
Shareholders’ equity 62 45 23 25 9 14 4 6 11 15
Returns, %
Returns, % ROA (31.27) (29.52) (44.22) (38.59) (109.46) (49.46) (77.02) (88.29) (45.76) (39.28)
ROIC (63.14) (39.21) (46.64) (48.08) 0.00 (376.70) (587.61) 0.00 (77.90) (184.28)
ROE (40.89) (38.82) (59.64) (54.15) (169.59) (65.29) (103.59) (181.00) (88.99) (65.58)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2023

Charts ten years each

Biodexa Pharmaceuticals PLC Unsponsored ADR vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
LYRA Lyra Therapeutics, Inc. $870.0K — (loss-making) — (loss-making) −96.65% (below 0%: shrinking) n/m +45.44% (above 0%: growing) 100.00% (101,685.71%) Compare
BTTX Better Therapeutics, Inc. $850.0K — (loss-making) — — n/m +20.43% (above 0%: growing) 0.00% 0.00% Compare
SEELQ Seelos Therapeutics, Inc. $700.0K — (loss-making) — (loss-making) +11.90% (above 0%: growing) n/m +83.54% (above 0%: growing) 100.00% (834.84%) Compare
ATXI Avenue Therapeutics, Inc. $680.0K — (loss-making) — (loss-making) — n/m −169.89% (below 0%: shrinking) 100.00% 0.00% Compare
SCNI Scinai Immunotherapeutics Ltd. Sponsored ADR $640.0K 0.0× — (loss-making) — n/m +51.13% (above 0%: growing) (228.63%) (504.50%) Compare
BDRX Biodexa Pharmaceuticals PLC Unsponsored ADR $440.0K — (loss-making) — −32.27% (below 0%: shrinking) +96.36% (above 0%: growing) −0.17% (below 0%: shrinking) 0.00% 0.00%
VINC Vincerx Pharma, Inc. $250.0K — (loss-making) — — n/m +42.45% (above 0%: growing) 0.00% 0.00% Compare
CDT CDT Equity Inc. $240.0K — (loss-making) — — n/m +78.92% (above 0%: growing) — 0.00% Compare
EFTR eFFECTOR Therapeutics, Inc. $200.0K — (loss-making) — +58.08% (above 0%: growing) n/m +4.86% (above 0%: growing) 0.00% 0.00% Compare
Median of peers $660.0K — — +11.90% — +43.95% 0.00% 0.00%

All 614 Biotechnology stocks →

Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) key facts

  • Concern: Biodexa Pharmaceuticals PLC Unsponsored ADR’s revenue for fiscal 2023 (year ended December 2023) was $473,900.00, down 45.2% from fiscal 2022.
  • Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, BDRX traded at $0.46, a market capitalization of $440,000.00.
  • Return on equity was −65.6% and debt-to-equity 0.00.
  • Its Altman Z-score is −21.37 (distress zone) for fiscal 2023.

Source: company filings (standardised) and stockrow calculations.

Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/BDRX · Data as of Dec 31, 2023 · For information only; not investment advice. · © 2026 stockrow.com